139140-55-9

Basic information

• Product Name: Silane, (1,1-dimethylethyl)(7-octynyloxy)diphenyl-
• CAS NO: 139140-55-9
• Molecular Formula: C24H32OSi
• Molecular Weight: 364.603
• Mol File: 139140-55-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Silane, (1,1-dimethylethyl)(7-octynyloxy)diphenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, (1,1-dimethylethyl)(7-octynyloxy)diphenyl-(139140-55-9)
• EPA Substance Registry System: Silane, (1,1-dimethylethyl)(7-octynyloxy)diphenyl-(139140-55-9)

Safety Data

• Hazardous Substances Data: 139140-55-9(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 871-91-0 oct-7-yn-1-ol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 14916-80-4 oct-3-yn-1-ol 

Downstream Products

• 139140-56-0 8-(4-methoxyphenyl)-7-octyn-1-yl tert-butyldiphenylsilyl ether 
• 622842-65-3 1-(tert-butyldiphenylsilyloxy)eicosa-7(Z)-en-20-ol 
• 622842-28-8 tert-butyl-diphenyl-[20-(tetrahydro-pyran-2-yloxy)-eicos-7-enyloxy]-silane 
• 622842-29-9 tert-butyl-diphenyl-[22-(tetrahydro-pyran-2-yloxy)-docos-7-enyloxy]-silane 

Relevant articles and documents

Synthesis and evaluation of simplified functionalized bongkrekic acid analogs

Bongkrekic acid (BKA) is a strong inhibitor of adenine nucleotide translocase (ANT), inducing inhibition of adenosine triphosphate synthesis. We designed and synthesized simplified benzene-ring-containing BKA analogs. The key reaction is the one-pot double Sonogashira reaction, which forms the main skeleton. The analogs were efficiently synthesized in 8–10 longest linear sequence steps. This synthetic method can be applied for the preparation of other analogs having different combinations of carbon chain lengths. Furthermore, the allyloxy group on the benzene ring can be easily replaced by other functional groups. Our preliminary biological evaluation based on mitochondrial inhibitory effects revealed the high potency of the analogs bearing the same carbon chain length as that of BKA. In particular, the prefunctionalized analogs are potential ANT inhibitors.

(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: High affinity leukotriene B4 receptor antagonists

(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid (11, SB 201993) is a novel, potent LTB4 receptor antagonist. Compound 11 arose from a structure-activity study of a series of trisubstituted pyridines that demonstrated LTB4 receptor antagonist activity. The placement of an additional methylene unit in the sulfur containing chain linking the pyridine and benzoic acid moieties of lead compound 8 (K(i) = 80 nM) resulted in a greater than 10-fold increase in receptor affinity. Additionally, in this new series of compounds, the oxidation state of the sulfur was found to be critical to the activity, i.e., the sulfoxide and sulfone showed substantially lower affinity for the LTB4 receptor. Compound 11 competitively inhibits the binding of [3H]LTB4 to LTB4 receptors on human polymorphonuclear leukocutes with a K(i) of 7.1 nM and blocks both the LTB4-induced calcium mobilization and the LTB4-induced degranulation responses in these cells with IC50 values of 131 and 271 nM, respectively. Compound 11 demonstrated oral LTB4 antagonist activity as well as topical antiinflammatory activity in the mouse.

(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]methyl]thio]methyl]benzoic acid: A novel high-affinity leukotriene B4 receptor antagonist

-